ADIL News & Events

Adial Pharmaceuticals announced the submission of the AD04 product application for consideration of the FDA Commissioner's National Priority Voucher Pilot Program. Announced in 2025, the CNPV program is designed to speed up the FDA review process for drugs that address one of five key U.S. national health priorities. It uses a collaborative review approach-similar to a "tumor board," where experts meet to discuss cases-to help evaluate applications more efficiently.

Adial Pharmaceuticals announced completion of the demonstration batch production for AD04. The results of the batch confirmed that the transferred process met the targeted specifications for the planned Phase 3 clinical batch and matched the dissolution profile of the previous Phase 2 batch, thereby demonstrating a technical process transfer. This important step was required prior to manufacturing the batch production for the planned Phase 3 clinical program. The tech transfer of the manufacturing and analytical capability for AD04 to a new CDMO resulted in significant efficiencies and crossing the hurdle of dissolution, blend and content uniformity which will have a meaningful clinical and commercial impact for AD04, once approved for patients suffering from AUD. This achievement enables the production of the clinical and registration batches which are required to conduct the clinical trial as well as the needed data for updates to the IND for AD04 with the Food and Drug Administration.

Cash and cash equivalents were $5.9 million as of December 31, 2025, compared to $3.8 million as of December 31, 2024. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the second half of 2026 based on currently committed development plans. "2025 was a pivotal year for Adial as we continued to advance AD04 scientifically, strategically, and within an evolving regulatory landscape," said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. "Our positive AD04-103 pharmacokinetic results, productive End-of-Phase 2 meeting with the FDA, and supportive FDA feedback on our in vitro bridging strategy provided meaningful validation of our clinical and regulatory approach. Engaging Cytel for advanced statistical design and partnering with Genomind for precision medicine testing further strengthens our ability to execute a rigorous and clinically relevant Phase 3 program."